[1] ROYCE MOHAN. Withaferin A is a potent inhibitor of angiogenesis[J]. Angiogenesis, 2004, 7 2: 115-122. DOI:
10.1007/s10456-004-1026-3[2] MARY KAILEH. Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity.[J]. The Journal of Biological Chemistry, 2007, 282 7: 4253-4264. DOI:
10.1074/jbc.m606728200[3] PAOLA BARGAGNA-MOHAN. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin.[J]. Chemistry & biology, 2007, 14 6: 623-634. DOI:
10.1016/j.chembiol.2007.04.010[4] JOSE T. THAIPARAMBIL. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation[J]. International Journal of Cancer, 2011, 129 11: 2744-2755. DOI:
10.1002/ijc.25938[5] IZHAR LIVNE-BAR. Pharmacologic inhibition of reactive gliosis blocks TNF-α-mediated neuronal apoptosis[J]. Cell Death & Disease, 2016, 7 9: e2386-e2386. DOI:
10.1038/cddis.2016.277